Authors:
Khan, OA
Zvartau-Hind, M
Caon, C
Din, MU
Cochran, M
Lisak, D
Tselis, AC
Kamholz, JA
Garbern, JY
Lisak, RP
Citation: Oa. Khan et al., Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy, MULT SCLER, 7(3), 2001, pp. 185-188
Authors:
Khan, OA
Tselis, AC
Kamholz, JA
Garbern, JY
Lewis, RA
Lisak, RP
Citation: Oa. Khan et al., A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFN beta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis, EUR J NEUR, 8(2), 2001, pp. 141-148
Citation: Sa. Shah et al., Behavioural and biomedical risk factors for the transmission of HIV/AIDS in Bangladesh, INT J STD A, 11(2), 2000, pp. 133-134
Authors:
Hyder, AA
Khan, OA
Shah, SA
Memon, MA
Khanani, MR
Ali, S
Citation: Aa. Hyder et al., Sub-national response in HIV/AIDS: a case study in AIDS prevention and control from Sindh province, Pakistan, PUBL HEAL, 113(1), 1999, pp. 39-43
Citation: Oa. Khan et Ss. Dhib-jalbut, Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MSpatients are cross-reactive, NEUROLOGY, 51(6), 1998, pp. 1698-1702